BPC-157 + TB-500 Stack vs Thymosin Beta-4 Fragment (TB4-Frag 17-23)
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157 + TB-500 Stack
The most widely researched peptide stack for tissue repair, combining BPC-157 (angiogenesis and growth factor upregulation) with TB-500 (actin regulation and cell migration). The two compounds address complementary and non-overlapping stages of the healing cascade, producing synergistic effects in tendon, ligament, muscle, and gut injury research models.
Full profileThymosin Beta-4 Fragment (TB4-Frag 17-23)
The heptapeptide fragment (amino acids 17–23) of full thymosin beta-4, sequence Ac-LKKTETQ. This sequence is the active actin-binding domain responsible for TB-500's tissue repair properties. Shorter molecular weight than TB-500 enables more targeted delivery while retaining identical mechanism of action on G-actin regulation and tissue repair signaling.
Full profile| BPC-157 + TB-500 Stack | Thymosin Beta-4 Fragment (TB4-Frag 17-23) | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Wolverine Stack, BPC TB500 combination, healing stack, BPC-157 TB-500 | TB4 fragment 17-23, TB-500 active peptide, LKKTETQ, thymosin beta-4 fragment, Ac-LKKTETQ |
| Evidence | Research-stage | Research-stage |
| Dosing range | BPC-157 250mcg + TB-500 2.5mg–BPC-157 750mcg + TB-500 7.5mg varies by component, 2–3x per week | 250mcg–1mg mcg–mg, 2–3x weekly |
| Administration | Subcutaneous injection, Intramuscular injection | Subcutaneous injection, Intramuscular injection |
| Key side effects | BPC-157: nausea (rare), dizziness, lightheadedness, TB-500: fatigue, headache, injection site reactions, No documented combination-specific adverse effects, Theoretical oncological considerations (angiogenesis stimulation) — relevant in cancer history | Injection site irritation, Mild fatigue (transient), Potential headache, Generally well-tolerated in research applications |
| Cited sources | 2 references | 2 references |
Key differences
- Dosing units differ: BPC-157 + TB-500 Stack is dosed in varies by component, Thymosin Beta-4 Fragment (TB4-Frag 17-23) in mcg–mg — they operate at different scales.
- Frequency: BPC-157 + TB-500 Stack is typically 2–3x per week; Thymosin Beta-4 Fragment (TB4-Frag 17-23) is 2–3x weekly.
How each works
BPC-157 + TB-500 Stack
BPC-157 and TB-500 work through entirely non-overlapping mechanisms and have been combined in numerous community protocols for injury recovery. BPC-157 drives angiogenesis and growth factor receptor expression; TB-500 regulates actin polymerization and cell migration into the injury site. No documented negative interactions exist — the combination is considered synergistic in the healing research community based on the complementary biology of each compound.
Thymosin Beta-4 Fragment (TB4-Frag 17-23)
The LKKTETQ sequence was identified in 1994 as the minimum active fragment of thymosin beta-4 responsible for its actin-sequestering and tissue repair activity. This heptapeptide competes with actin monomer binding proteins, promoting cell migration, angiogenesis, and wound healing. Studies confirm it recapitulates the key bioactivity of full TB4 in cell migration and collagen deposition assays.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.